RECCE PHARMACEUTICALS LTD — Director's Dealing 2020

Jul 12, 2020

Appendix 3Y

Rule 3.19A.2

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

	Name of entity Recce Pharmaceuticals Ltd (Company)
ACN	124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michele Keryn Dilizia
Date of last notice	14 August 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	N/A
Date of change	9 July 2020
No. of securities held prior to change	2,654,061 fully paid ordinary shares
	577,212 Class B Performance Shares
	577,212 Class C Performance Shares
	577,212 Class D Performance Shares
Class	Fully paid ordinary shares and Class CPerformance Shares
Number acquired	577,212 fully paid ordinary shares (uponconversionof577,212ClassCPerformance Shares)
Number disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	Nil

+ See chapter 19 for defined terms.

No. of securities held after change	3,231,273 fully paid ordinary shares
	577,212 Class B Performance Shares
	577,212 Class D Performance Shares
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back	Conversionof577,212ClassCPerformance Shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior tochangeNote: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above	No
traded during a +closed period whereprior written clearance was
required?

+ See chapter 19 for defined terms.

If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

+ See chapter 19 for defined terms.